Immune Response Drives Outcomes in Prostate Cancer: Implications for Immunotherapy
J. Meng, Y. Zhou, X. Lu…·C. Liang
This study identifies an immune class in prostate cancer associated with better recurrence-free survival and response to anti-PD-1/PD-L1 immunotherapy.